Company / SG&A Expense
Abbott Laboratories SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$12.3B
FY2025
5-year range
$9.7B / $12.3B
FY2021-FY2025
Trend
+5.4%
vs FY2024
Sector context
#7 of 158
Health Care
What the data says
Among 158 Health Care companies, Abbott Laboratories is in the bottom 4% for sg&a expense. SG&A Expense has increased for 3 consecutive years, from $9.7B in FY2022 to $12.3B in FY2025.
Based on SEC 10-K filings.
$12.3B in FY2025 with a 5-year CAGR of +4.8%. Top quartile in the Health Care sector.
Increased from $11.3B to $12.3B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +8.3%
- 5-Year CAGR
- +4.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 158This company $12.3B Sector average $175.9B
▼
-93.0% below sector average
Key checks
Key Insights
- Abbott Laboratories's sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +4.8%, indicating consistent growth.
- In FY2025, sg&a expense increased 5.4% year-over-year.
- Ranks #7 out of 158 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 31.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 27.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.3B | +5.4% |
| FY2024 | $11.7B | +3.3% |
| FY2023 | $11.3B | +16.8% |
| FY2022 | $9.7B | -0.7% |
| FY2021 | $9.8B | +0.2% |
| FY2020 | $9.7B | -0.2% |
| FY2019 | $9.8B | +45.0% |
| FY2018 | $6.7B | -0.7% |
| FY2017 | $6.8B | +3.9% |
| FY2016 | $6.5B | +2.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026